U.S. markets closed

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
1.6000-0.0500 (-3.03%)
Al cierre: 04:00PM EDT

Cumberland Pharmaceuticals Inc.

1600 West End Avenue
Suite 1300
Nashville, TN 37203
United States
615 255 0068
https://www.cumberlandpharma.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo91

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. A. J. Kazimi MBAFounder, Chairman, President & CEO952.53kN/D1958
Mr. John Michael HammVP & CFO258.38kN/D1956
Mr. James Lowrance HermanExecutive VP of National Accounts & Chief Compliance Officer372.27kN/D1955
Mr. Chris T. BittermanVice President of Sales & Marketing290.87kN/D1965
Mr. Todd M. AnthonyVice President of Organizational Development304.94kN/D1961
Ms. Jean W. MarstillerSenior VP of Administrative Services & Corporate Secretary282.17k38.53k1950
Ms. Erin Smith GullSenior Corporate Relations AssociateN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Gestión corporativa

La calificación ISS Governance QuickScore de Cumberland Pharmaceuticals Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.